BrainStorm Cell Therapeutics Inc. is currently conducting a Phase I/II clinical trial to collect preliminary efficacy data as well as test the tolerability and safety of their NurOwn technology for the treatment of ALS. On January 7, 2013, BrainStorm announced that its Phase I/II trial has been fast tracked to a Phase IIa dose-escalating trial by the Israeli Ministry of Health. BrainStorm’s CEO, Dr. Adrian Harel, said “Acceleration to Phase IIa will save us critical time, enabling us to proceed much more quickly with achieving our goal of developing an effective treatment for ALS.” In other exciting news, BrainStorm was recently awarded a 3 million NIS grant from Israel’s Office of the Chief Scientist (OCS). The grant money will be used to support further development of BrainStorm’s NurOwn mesenchymal stem cell technology for the treatment of ALS. Furthermore, BrainStrom announced on December 17 that they had partnered with Octane Biotech of Kingston, Ontario, Canada to develop a bioreactor that will be used for the production of stem cells. On Monday, January 14, BrainStorm will hold an international conference call to discuss these exciting recent developments. The call will be broadcast in Hebrew at 8:00 am and in English at 8:45 am. Read all of these stories in more detail and find out how to join the call at BrainStorm’s website (http://www.brainstorm-cell.com/).
Click here to read more.Share this: